REC-CAGEFREE II, NOTION-2, LANDMARK: Three major late-breaking trials presented at EuroPCR 2024

The first Hotline/Late-Breaking Trials session of EuroPCR addressed some hugely important questions in coronary and structural heart disease. Learn all about the results!

The Course Directors have selected 3 major Late Breaking Trials (LBTs) that were presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice.

One-month DAPT followed by 5-month Ticagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Presented by Ling Tao, this pioneering study provides the 1st randomised data concerning the use of antiplatelet therapy in ACS patients treated with DCB, but results are mostly applicable to low-risk populations (unstable angina w/ single small vessel disease).

Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial

Results of the LANDMARK trial, presented by Patrick Serruys: Previous head-to-head comparisons of new THVs with established devices confirmed no class effect of clinical benefits after TAVI with inferior safety & efficacy for some of them. Validation of MyVal non-inferiority to the most widely used balloon-expandable and self-expandable platforms is therefore significant.

Short-term data from NOTION-2: TAVR versus SAVI for younger patients with aortic stenosis

Presented by Ole De Backer, this study provides further data concerning the 1-year outcome of younger AS patients with tricuspid valve anatomy treated with TAVI compared to SAVR. TAVI and SAVR showed similar rates of the primary endpoint at 1 year, but this interpretation is limited by the small sample size.
It also provides a “word of caution” concerning the use of TAVI in younger AS patients with bicuspid valve anatomy: dedicated trials comparing optimal TAVI with SAVR in younger patients with bicuspid aortic valve stenosis are now required.